Review
Nature Reviews Cancer 1, 194-202 (December 2001) | doi:10.1038/35106079
Histone deacetylases and cancer: causes and therapies
Paul A. Marks1, Richard A. Rifkind1, Victoria M. Richon1, Ronald Breslow2, Thomas Miller2 & William K. Kelly1 About the authors
Abstract
Together, histone acetyltransferases and histone deacetylases (HDACs) determine the acetylation status of histones. This acetylation affects the regulation of gene expression, and inhibitors of HDACs have been found to cause growth arrest, differentiation and/or apoptosis of many tumours cells by altering the transcription of a small number of genes. HDAC inhibitors are proving to be an exciting therapeutic approach to cancer, but how do they exert this effect?
- View At a Glance
Author affiliations
- Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.
- Columbia University, New York, New York 10027, USA.
Correspondence to: Paul A. Marks1 Email: paula_marks@mskcc.org